Cargando…

Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature

INTRODUCTION: To date, with no prophylactic human immunodeficiency virus (HIV) vaccine available, HIV incidence rates remain undefeated. Despite full virological suppression, HIV+ individuals exhibit a higher rate of cardiovascular disorders and cancers what is attributed to the residual, persistent...

Descripción completa

Detalles Bibliográficos
Autores principales: Sips, Magdalena, Gerlo, Sarah, De Clercq, Laura, Gomez, Esteban A., Colas, Romain A., Dalli, Jesmond, Vandekerckhove, Linos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138705/
https://www.ncbi.nlm.nih.gov/pubmed/35634953
http://dx.doi.org/10.1002/iid3.629
_version_ 1784714686884741120
author Sips, Magdalena
Gerlo, Sarah
De Clercq, Laura
Gomez, Esteban A.
Colas, Romain A.
Dalli, Jesmond
Vandekerckhove, Linos
author_facet Sips, Magdalena
Gerlo, Sarah
De Clercq, Laura
Gomez, Esteban A.
Colas, Romain A.
Dalli, Jesmond
Vandekerckhove, Linos
author_sort Sips, Magdalena
collection PubMed
description INTRODUCTION: To date, with no prophylactic human immunodeficiency virus (HIV) vaccine available, HIV incidence rates remain undefeated. Despite full virological suppression, HIV+ individuals exhibit a higher rate of cardiovascular disorders and cancers what is attributed to the residual, persistent levels of immune activation. METHODS: We have established the Virological and Immunological Monitoring (VIM) platform and forty VIM samples that included treated immunological responders (IRs) or nonresponders (INRs), viremic untreated subjects and uninfected controls, were phenotyped by flow cytometry and plasma was used to quantify proinflammatory eicosanoids and the specialized proresolving mediators by liquid chromatography tandem mass spectrometry. RESULTS: While HIV infection profoundly altered lipid mediator (LM) profile, differences were also seen in patients on viral suppressive therapy. IRs exhibited higher levels of proresolving mediators as compared to INRs and notable differences in plasma LM were also seen in early and late treated individuals. CONCLUSIONS: This study demonstrated distortions in proinflammatory/proresolution processes in infected patients including those with controlled viremia.
format Online
Article
Text
id pubmed-9138705
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91387052022-06-04 Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature Sips, Magdalena Gerlo, Sarah De Clercq, Laura Gomez, Esteban A. Colas, Romain A. Dalli, Jesmond Vandekerckhove, Linos Immun Inflamm Dis Short Reports INTRODUCTION: To date, with no prophylactic human immunodeficiency virus (HIV) vaccine available, HIV incidence rates remain undefeated. Despite full virological suppression, HIV+ individuals exhibit a higher rate of cardiovascular disorders and cancers what is attributed to the residual, persistent levels of immune activation. METHODS: We have established the Virological and Immunological Monitoring (VIM) platform and forty VIM samples that included treated immunological responders (IRs) or nonresponders (INRs), viremic untreated subjects and uninfected controls, were phenotyped by flow cytometry and plasma was used to quantify proinflammatory eicosanoids and the specialized proresolving mediators by liquid chromatography tandem mass spectrometry. RESULTS: While HIV infection profoundly altered lipid mediator (LM) profile, differences were also seen in patients on viral suppressive therapy. IRs exhibited higher levels of proresolving mediators as compared to INRs and notable differences in plasma LM were also seen in early and late treated individuals. CONCLUSIONS: This study demonstrated distortions in proinflammatory/proresolution processes in infected patients including those with controlled viremia. John Wiley and Sons Inc. 2022-05-27 /pmc/articles/PMC9138705/ /pubmed/35634953 http://dx.doi.org/10.1002/iid3.629 Text en © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Sips, Magdalena
Gerlo, Sarah
De Clercq, Laura
Gomez, Esteban A.
Colas, Romain A.
Dalli, Jesmond
Vandekerckhove, Linos
Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
title Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
title_full Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
title_fullStr Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
title_full_unstemmed Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
title_short Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
title_sort distinct immune profiles of hiv‐infected subjects are linked to specific lipid mediator signature
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138705/
https://www.ncbi.nlm.nih.gov/pubmed/35634953
http://dx.doi.org/10.1002/iid3.629
work_keys_str_mv AT sipsmagdalena distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature
AT gerlosarah distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature
AT declercqlaura distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature
AT gomezestebana distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature
AT colasromaina distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature
AT dallijesmond distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature
AT vandekerckhovelinos distinctimmuneprofilesofhivinfectedsubjectsarelinkedtospecificlipidmediatorsignature